IP Library Granted Patent US 10,640,542
Granted Patent B2
US 10,640,542 · App. 14/905,343 · Granted May 5, 2020

Fusokines involving cytokines with strongly reduced receptor binding affinities

Inventors: Jan Tavernier (Balegem, BE); Jennyfer Bultinck (Ledeberg, BE); Sarah Gerlo (Ghent, BE); Gilles Uze (Montpellier, FR); Franciane Paul (Montpellier, FR); Yann Bordat (Montpellier, FR)
Assignees: VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITÉ MONTPELLIER 2; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
C07K14/521A61K38/195A61K38/2006A61P37/04C07K14/52C07K14/523C07K14/525C07K14/545C07K14/56C07K14/5759C07K2319/00C07K2319/33C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,640,542
App. No.
14/905,343
Granted
May 5, 2020
Kind
B2
Abstract

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

Claims (6)

1. A composition comprising a fusion protein comprising at least two cytokines, wherein the cytokines are CC chemokine 20 (CCL20) and mutant human interleukin-1 beta (IL-1β) and wherein IL-1β comprises a mutation selected from R120G, Q131G, H146A, and Q148G that reduces binding activity of IL-1β to its receptor as compared to wild type IL-1β, and the CCL20 is wild-type and provides cell-specific targeting that restores activity of the mutant IL-1β on the targeted cells.

2. The composition of claim 1 , further comprising a GGS linker.

3. The composition of claim 1 , wherein the human IL-1β mutation is Q148G.

4. The composition of claim 1 , wherein the human IL-1β mutation is R120G.

5. The composition of claim 1 , wherein the human IL-1β mutation is Q131G.

6. The composition of claim 1 , wherein the human IL-1β mutation is H146A.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jun 15, 2018
From: UNIVERSITÉ MONTPELLIER 2; UNIVERSITÉ DE MONTPELLIER
To: UNIVERSITÉ DE MONTPELLIER
Reel/Frame 046376/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2016
From: TAVERNIER, JAN; BULTINCK, JENNYFER; GERLO, SARAH; UZE, GILLES; PAUL, FRANCIANE; BORDAT, YANN
To: VIB VZW; UNIVERSITEIT GENT; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITÉ MONTPELLIER 2; CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
Reel/Frame 038318/0816 →
Priority Claims (1)
EP 13306034 · Jul 18, 2013 · regional
Continuity (1)
Related Publication 20180155404A1 · Jun 7, 2018
Cited By (13)
US 12,226,440 US 12,318,419 US 12,351,614 US 12,351,633 US 12,403,165 US 12,410,225 US 12,448,447 US 12,472,217 US 12,473,338 US 12,576,127 US 12,583,898 US 12,583,941 US 12,655,186